Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PLAGL1
REST API REST API
Homo sapiens
PLAGL1 is differentially expressed in 334 experiments: 163 organism parts: placenta, liver, ... (161 more);, 213 disease states: normal, benign prostatic hyperplasia, ... (211 more);, 102 cell types 520 cell lines 38 compound treatments and 75 other conditions.
Synonyms ZAC, LOT1
Orthologs Plagl1 (Mus musculus)   Q52NW6_BOVIN (Bos taurus)   PLAGL1 (Gallus gallus)   Plagl1 (Rattus norvegicus)   PLAGL1 (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, intracellular, cell cycle arrest, metal ion binding, nucleic acid binding, induction of apoptosis, positive regulation of transcription from RNA polymerase II promoter, nucleus, regulation of gene expression, zinc ion binding
UniProt Accession A1YLA1, Q9UM63, Q5TFH3, Q68DN7
Gene-Disease Assocation DIABETES MELLITUS, TRANSIENT NEONATAL, 1
Search EB-eye ENSG00000118495
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, ... (50 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
Raji
2
E-GEOD-96, E-MTAB-37
primary culture
2
E-GEOD-2450, E-GEOD-1657
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
514 more value(s).


Cell type

studied in E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-GEOD-21750, E-TABM-34, ... (50 experiments)

Factor Value U/D Experiments
CD4+ T cell
3
E-AFMX-5, E-MTAB-24, E-MTAB-25
CD34+
2
E-AFMX-5, E-TABM-145
mononuclear cell
2
E-GEOD-6053, E-MEXP-66
monocyte
1
2
E-GEOD-22373, E-MEXP-583, E-GEOD-5099
platelet
1
E-GEOD-2006
CXCR5(lo)ICOS(int) CD4 T cell
1
E-MEXP-750
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (76 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-6014, E-GEOD-4412, E-MTAB-62
acute promyelocytic leukemia
3
E-GEOD-96, E-MTAB-62, E-GEOD-1729
lung adenocarcinoma
3
E-MTAB-62, E-GEOD-2514, E-MEXP-231
prostate carcinoma
1
3
E-MTAB-62, E-GEOD-3868, E-TABM-26, E-MEXP-2034
Crohn's disease
2
E-GEOD-6731, E-GEOD-3365
leiomyosarcoma
2
E-MEXP-1922, E-MTAB-62
207 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-GEOD-5099, ... (24 experiments)

Factor Value U/D Experiments
interleukin-22 (Homo sapiens)
1
E-GEOD-7216
Cxcl12
1
1
E-GEOD-7307
unknown
1
E-GEOD-7307
interferon alpha
1
E-GEOD-1740
granulocyte-macrophage colony-stimulating factor + interferon alpha
1
E-MEXP-2000
vanadium pentoxide
1
E-GEOD-5339
32 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, ... (8 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-22148, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-22593, E-TABM-321, E-GEOD-20115, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (40 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-980, E-GEOD-17400, E-GEOD-360 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896, E-GEOD-17204

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (8 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-TABM-147

Tumor size
studied in E-GEOD-6532

Processing time: 0.323 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM